BioTuesdays

Tag - CAPR

Capricor Therapeutics

HCW lowers Capricor Therapeutics PT to $9

H.C. Wainwright lowered its price target for Capricor Therapeutics (NASDAQ:CAPR) to $9.50 based on a higher fully diluted share count but maintained its “buy” rating. The stock closed at $1.83 on Jan. 17. Analyst Joseph...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.